Ultragenyx Pharmaceutical (RARE) Stock Price, Quote, News & History | Benzinga

Ultragenyx Pharmaceutical Inc (RARE) Stock Price, Quote, News & History

RARENASDAQ

Trade with Public

Trade with Public

$14.85

-11.68-44.03%

At close: Sep 2, 5:00 PM EST

$15.01

-11.52-43.42%

Pre-Market: 4:37 AM EST

PRO

Why Is It Moving?™:Ultragenyx Pharmaceutical shares are trading lower after the company announ...

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$14.85

Volume / Avg.

33.78K / 2.79M

Day Range

- - -

52 Wk Range

13.81 - 39.89

Market Cap

$1.48B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

20

Short Interest

16.67%

Days to Cover

7.78

Recent Ultragenyx Pharmaceutical Inc. News

QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target

Martin Shkreli calls Ultragenyx undervalued and a takeover target as the stock tanks after a trial failure.

Erica Kollmann

Gold Jumps 3%; ISM Services PMI Rises In August

U.S. stocks climbed, led by Dow’s 600-point gain; services PMI strengthened, Snowflake surged, while Ultragenyx plunged 44%.

Avi Kapoor

Nasdaq Gains Over 200 Points; US Weekly Jobless Claims Edge Higher

U.S. stocks climbed, led by Nasdaq; communications shares rose, energy fell, while MIMI surged and RARE plunged after trial failures.

Avi Kapoor

Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Results

Ultragenyx reports Phase 3 Aspire study of apazunersen failed to meet primary endpoints, prompting plans for expense cuts.

Vandana Singh

This Sonoco Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Analysts downgraded Ultragenyx, Moderna and Sonoco; targets fell for RARE and SON but rose for MRNA.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-485.00M

Investing Cash Flow (TTM)

40.00M

Financing Cash Flow (TTM)

397.00M

Free Cash Flow (TTM)

-494.00M

Capital Expenditure (TTM)

-9.00M

Net Change in Cash (TTM)

-

Analyst Trends and Forecast

3

2

May

1

Jul

10

Aug

7

4

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$819.06M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

2.08

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-39.29%

Earnings Yield % (FWD)

-4.72%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$2.95

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$125.00M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$14.85

Volume / Avg.

33.78K / 2.79M

Day Range

- - -

52 Wk Range

13.81 - 39.89

Market Cap

$1.48B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

20

Short Interest

16.67%

Days to Cover

7.78

About

Sector

Health Care

Industry

Biotechnology

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic co...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Ultragenyx Pharmaceutical (RARE) stock?

A

You can purchase shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Ultragenyx Pharmaceutical (RARE) competitors?

A

Other companies in Ultragenyx Pharmaceutical’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Ultragenyx Pharmaceutical (RARE) stock?

A

Ultragenyx Pharmaceutical has a consensus price target of $52.12.

Q

What is the current price for Ultragenyx Pharmaceutical (RARE)?

A

The stock price for Ultragenyx Pharmaceutical (NASDAQ: RARE) is $15.01 last updated September 4, 2026 at 4:38 AM EDT.

Q

Does Ultragenyx Pharmaceutical (RARE) pay a dividend?

A

There are no upcoming dividends for Ultragenyx Pharmaceutical.

Q

When is Ultragenyx Pharmaceutical (NASDAQ:RARE) reporting earnings?

A

Ultragenyx Pharmaceutical does not have any upcoming earnings scheduled.

Q

Is Ultragenyx Pharmaceutical (RARE) going to split?

A

There is no upcoming split for Ultragenyx Pharmaceutical.

Q

What sector and industry does Ultragenyx Pharmaceutical (RARE) operate in?

A

Ultragenyx Pharmaceutical is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.